Vera Bradley Foundation for Breast Cancer Research investigators at IU School of Medicine know that to improve breast cancer treatment, they must design therapies that consider both the genetics of the tumor and the individual it has invaded. Threading these intricate strands of information together allow for therapies tailored to each patient– precision therapeutics that are best tolerated by the patient and that precisely target their tumor. The future of breast cancer care is monogrammed medicine, personalized for each individualized patient.
Cancer has traditionally been described by its organ of origin, but what was previously assumed to be a single cancer is not. Rather, under the umbrella of breast cancer are numerous distinct diseases. While incremental strides have been made to identify the nuances of each sub-type, the treatment regimen has remained more or less the same: cut out the cancer and blast the patient with toxic drugs that kill healthy cells along with the bad ones. It is an imprecise science at a time when precision is demanded.
With the establishment of monogrammed medicine, IU School of Medicine researchers are developing unique treatment models for patients by analyzing both the genetics of the tumor and the person at hand. Every patient’s treatment will be defined by the exact therapy that works best for them. Advances in cancer make it clear that this type of customized treatment is what breast cancer care of the future must entail. Thanks to the Vera Bradley Foundation for Breast Cancer’s unprecedented support, nowhere in the world is better positioned to lead this work than the breast cancer team at the Indiana University Melvin and Bren Simon Cancer Center at IU School of Medicine.
The future of breast cancer care is monogrammed medicine, personalized precisely for the patient.